Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): Results from the non-Hodgkin's lymphoma classification project

T. Rüdiger, D. D. Weisenburger, J. R. Anderson, James Olen Armitage, J. Diebold, K. A. MacLennan, B. N. Nathwani, F. Ullrich, H. K. Müller-Hermelink

Research output: Contribution to journalArticle

337 Citations (Scopus)

Abstract

Background: Peripheral T-cell lymphoma (PTCL) is rare in most parts of the world. Therefore, we have evaluated the 96 cases of PTCL diagnosed within the Non-Hodgkin's Lymphoma Classification Project (NHLCP) (1378 cases) for their geographical distribution, pathologic features and diagnostic reliability, as well as clinical presentation and outcome. Materials and methods: Diagnoses of all cases were rendered independently by five experienced hematopathologists based on morphology only, and after introduction of the immunophenotype and clinical data. Divergent diagnoses were jointly discussed and a final consensus diagnosis was established in each case. Reliability of the diagnoses was evaluated statistically, and the clinical features and outcome were analyzed according to the consensus diagnoses. Results: Seven per cent of all non-Hodgkin's lymphoma (NHL) cases reviewed were classified as PTCL and the frequency varied from 1.5% to 18.3% in different countries. The interobserver agreement with the consensus diagnosis of PTCL was 86% in the Revised European-American Lymphoma (REAL) classification, but the designation of subtypes was less reliable. Diagnostic reliability improved from 41% to 86% after immunophenotyping, but did not improve further with the addition of detailed clinical data. Clinically, angiocentric nasal lymphoma presented in young females (median age 49 years) at extranodal sites, but with few adverse risk factors, whereas angioimmunoblastic lymphoma presented most often in older males (median age 65 years) at nodal and extranodal sites with numerous risk factors. The 5-year overall and failure-free survivals for patients with PTCL treated with doxorubicin (Adriamycin)-containing regimens were only 26% and 20%, respectively. Both failure-free and overall survival were strongly correlated with the performance status and International Prognostic Index scores at presentation, but differences in survival were not observed between the major histological types. However, within the PTCL 'not otherwise specified' category, but not angioimmunoblastic lymphoma, the number of transformed blasts was prognostically relevant. Conclusions: PTCLs can be diagnosed reliably by experienced hematopathologists, but immunophenotyping is absolutely necessary. Currently, all types of PTCL should be considered high-grade lymphomas. An increased ability to distinguish T-lymphocyte subsets is needed in order to better subclassify the PTCLs for therapeutic and prognostic purposes.

Original languageEnglish (US)
Pages (from-to)140-149
Number of pages10
JournalAnnals of Oncology
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2002

Fingerprint

Peripheral T-Cell Lymphoma
Anaplastic Large-Cell Lymphoma
Non-Hodgkin's Lymphoma
Lymphoma
Immunophenotyping
Doxorubicin
Survival
T-Lymphocyte Subsets
Nose

Keywords

  • Clinicopathologic correlations
  • Diagnostic reliability
  • Peripheral T-cell lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Rüdiger, T., Weisenburger, D. D., Anderson, J. R., Armitage, J. O., Diebold, J., MacLennan, K. A., ... Müller-Hermelink, H. K. (2002). Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): Results from the non-Hodgkin's lymphoma classification project. Annals of Oncology, 13(1), 140-149. https://doi.org/10.1093/annonc/mdf033

Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma) : Results from the non-Hodgkin's lymphoma classification project. / Rüdiger, T.; Weisenburger, D. D.; Anderson, J. R.; Armitage, James Olen; Diebold, J.; MacLennan, K. A.; Nathwani, B. N.; Ullrich, F.; Müller-Hermelink, H. K.

In: Annals of Oncology, Vol. 13, No. 1, 01.01.2002, p. 140-149.

Research output: Contribution to journalArticle

Rüdiger, T, Weisenburger, DD, Anderson, JR, Armitage, JO, Diebold, J, MacLennan, KA, Nathwani, BN, Ullrich, F & Müller-Hermelink, HK 2002, 'Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): Results from the non-Hodgkin's lymphoma classification project', Annals of Oncology, vol. 13, no. 1, pp. 140-149. https://doi.org/10.1093/annonc/mdf033
Rüdiger, T. ; Weisenburger, D. D. ; Anderson, J. R. ; Armitage, James Olen ; Diebold, J. ; MacLennan, K. A. ; Nathwani, B. N. ; Ullrich, F. ; Müller-Hermelink, H. K. / Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma) : Results from the non-Hodgkin's lymphoma classification project. In: Annals of Oncology. 2002 ; Vol. 13, No. 1. pp. 140-149.
@article{a6ac7b9cc1304c8388970d656a77004d,
title = "Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): Results from the non-Hodgkin's lymphoma classification project",
abstract = "Background: Peripheral T-cell lymphoma (PTCL) is rare in most parts of the world. Therefore, we have evaluated the 96 cases of PTCL diagnosed within the Non-Hodgkin's Lymphoma Classification Project (NHLCP) (1378 cases) for their geographical distribution, pathologic features and diagnostic reliability, as well as clinical presentation and outcome. Materials and methods: Diagnoses of all cases were rendered independently by five experienced hematopathologists based on morphology only, and after introduction of the immunophenotype and clinical data. Divergent diagnoses were jointly discussed and a final consensus diagnosis was established in each case. Reliability of the diagnoses was evaluated statistically, and the clinical features and outcome were analyzed according to the consensus diagnoses. Results: Seven per cent of all non-Hodgkin's lymphoma (NHL) cases reviewed were classified as PTCL and the frequency varied from 1.5{\%} to 18.3{\%} in different countries. The interobserver agreement with the consensus diagnosis of PTCL was 86{\%} in the Revised European-American Lymphoma (REAL) classification, but the designation of subtypes was less reliable. Diagnostic reliability improved from 41{\%} to 86{\%} after immunophenotyping, but did not improve further with the addition of detailed clinical data. Clinically, angiocentric nasal lymphoma presented in young females (median age 49 years) at extranodal sites, but with few adverse risk factors, whereas angioimmunoblastic lymphoma presented most often in older males (median age 65 years) at nodal and extranodal sites with numerous risk factors. The 5-year overall and failure-free survivals for patients with PTCL treated with doxorubicin (Adriamycin)-containing regimens were only 26{\%} and 20{\%}, respectively. Both failure-free and overall survival were strongly correlated with the performance status and International Prognostic Index scores at presentation, but differences in survival were not observed between the major histological types. However, within the PTCL 'not otherwise specified' category, but not angioimmunoblastic lymphoma, the number of transformed blasts was prognostically relevant. Conclusions: PTCLs can be diagnosed reliably by experienced hematopathologists, but immunophenotyping is absolutely necessary. Currently, all types of PTCL should be considered high-grade lymphomas. An increased ability to distinguish T-lymphocyte subsets is needed in order to better subclassify the PTCLs for therapeutic and prognostic purposes.",
keywords = "Clinicopathologic correlations, Diagnostic reliability, Peripheral T-cell lymphoma",
author = "T. R{\"u}diger and Weisenburger, {D. D.} and Anderson, {J. R.} and Armitage, {James Olen} and J. Diebold and MacLennan, {K. A.} and Nathwani, {B. N.} and F. Ullrich and M{\"u}ller-Hermelink, {H. K.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1093/annonc/mdf033",
language = "English (US)",
volume = "13",
pages = "140--149",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma)

T2 - Results from the non-Hodgkin's lymphoma classification project

AU - Rüdiger, T.

AU - Weisenburger, D. D.

AU - Anderson, J. R.

AU - Armitage, James Olen

AU - Diebold, J.

AU - MacLennan, K. A.

AU - Nathwani, B. N.

AU - Ullrich, F.

AU - Müller-Hermelink, H. K.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Background: Peripheral T-cell lymphoma (PTCL) is rare in most parts of the world. Therefore, we have evaluated the 96 cases of PTCL diagnosed within the Non-Hodgkin's Lymphoma Classification Project (NHLCP) (1378 cases) for their geographical distribution, pathologic features and diagnostic reliability, as well as clinical presentation and outcome. Materials and methods: Diagnoses of all cases were rendered independently by five experienced hematopathologists based on morphology only, and after introduction of the immunophenotype and clinical data. Divergent diagnoses were jointly discussed and a final consensus diagnosis was established in each case. Reliability of the diagnoses was evaluated statistically, and the clinical features and outcome were analyzed according to the consensus diagnoses. Results: Seven per cent of all non-Hodgkin's lymphoma (NHL) cases reviewed were classified as PTCL and the frequency varied from 1.5% to 18.3% in different countries. The interobserver agreement with the consensus diagnosis of PTCL was 86% in the Revised European-American Lymphoma (REAL) classification, but the designation of subtypes was less reliable. Diagnostic reliability improved from 41% to 86% after immunophenotyping, but did not improve further with the addition of detailed clinical data. Clinically, angiocentric nasal lymphoma presented in young females (median age 49 years) at extranodal sites, but with few adverse risk factors, whereas angioimmunoblastic lymphoma presented most often in older males (median age 65 years) at nodal and extranodal sites with numerous risk factors. The 5-year overall and failure-free survivals for patients with PTCL treated with doxorubicin (Adriamycin)-containing regimens were only 26% and 20%, respectively. Both failure-free and overall survival were strongly correlated with the performance status and International Prognostic Index scores at presentation, but differences in survival were not observed between the major histological types. However, within the PTCL 'not otherwise specified' category, but not angioimmunoblastic lymphoma, the number of transformed blasts was prognostically relevant. Conclusions: PTCLs can be diagnosed reliably by experienced hematopathologists, but immunophenotyping is absolutely necessary. Currently, all types of PTCL should be considered high-grade lymphomas. An increased ability to distinguish T-lymphocyte subsets is needed in order to better subclassify the PTCLs for therapeutic and prognostic purposes.

AB - Background: Peripheral T-cell lymphoma (PTCL) is rare in most parts of the world. Therefore, we have evaluated the 96 cases of PTCL diagnosed within the Non-Hodgkin's Lymphoma Classification Project (NHLCP) (1378 cases) for their geographical distribution, pathologic features and diagnostic reliability, as well as clinical presentation and outcome. Materials and methods: Diagnoses of all cases were rendered independently by five experienced hematopathologists based on morphology only, and after introduction of the immunophenotype and clinical data. Divergent diagnoses were jointly discussed and a final consensus diagnosis was established in each case. Reliability of the diagnoses was evaluated statistically, and the clinical features and outcome were analyzed according to the consensus diagnoses. Results: Seven per cent of all non-Hodgkin's lymphoma (NHL) cases reviewed were classified as PTCL and the frequency varied from 1.5% to 18.3% in different countries. The interobserver agreement with the consensus diagnosis of PTCL was 86% in the Revised European-American Lymphoma (REAL) classification, but the designation of subtypes was less reliable. Diagnostic reliability improved from 41% to 86% after immunophenotyping, but did not improve further with the addition of detailed clinical data. Clinically, angiocentric nasal lymphoma presented in young females (median age 49 years) at extranodal sites, but with few adverse risk factors, whereas angioimmunoblastic lymphoma presented most often in older males (median age 65 years) at nodal and extranodal sites with numerous risk factors. The 5-year overall and failure-free survivals for patients with PTCL treated with doxorubicin (Adriamycin)-containing regimens were only 26% and 20%, respectively. Both failure-free and overall survival were strongly correlated with the performance status and International Prognostic Index scores at presentation, but differences in survival were not observed between the major histological types. However, within the PTCL 'not otherwise specified' category, but not angioimmunoblastic lymphoma, the number of transformed blasts was prognostically relevant. Conclusions: PTCLs can be diagnosed reliably by experienced hematopathologists, but immunophenotyping is absolutely necessary. Currently, all types of PTCL should be considered high-grade lymphomas. An increased ability to distinguish T-lymphocyte subsets is needed in order to better subclassify the PTCLs for therapeutic and prognostic purposes.

KW - Clinicopathologic correlations

KW - Diagnostic reliability

KW - Peripheral T-cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0036228950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036228950&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdf033

DO - 10.1093/annonc/mdf033

M3 - Article

C2 - 11863096

AN - SCOPUS:0036228950

VL - 13

SP - 140

EP - 149

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -